Featured Research

from universities, journals, and other organizations

Added benefit of lisdexamfetamine is not proven

Date:
September 3, 2013
Source:
Institute for Quality and Efficiency in Health Care
Summary:
A short-term study on the new ADHD drug lisdexamfetamine was unsuitable for several reasons, mainly because the treatment was not conducted as part of a comprehensive treatment program, and no added benefit of the drug can be derived.

Lisdexamfetamine dimesylate (trade name: Elvanse) has been approved in Germany since March 2013 as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous treatment with the drug methylphenidate was inadequate. No added benefit of the drug versus the appropriate comparator therapy could be established in the assessment of the drug manufacturer's dossier according to the Act on the Reform of the Market for Medicinal Products (AMNOG). The manufacturer did not present any relevant studies. This was the result of the report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 2 September 2013.

Medication only as part of a comprehensive treatment programme

Both lisdexamfetamine (short for lisdexamfetamine dimesylate) and the appropriate comparator therapy specified by the Federal Joint Committee (G-BA) atomoxetine are approved for administration as part of a comprehensive treatment programme (multimodal treatment for ADHD). According to the Summaries of Product Characteristics (SPC) of these drugs, a comprehensive treatment programme typically includes psychological, educational and social measures. The SPC of lisdexamfetamine additionally regards appropriate educational placement as "essential" and psychosocial intervention as "generally necessary."

Moreover, according to the G-BA's Pharmaceutical Directive, both drugs as stimulants in ADHD can only be prescribed at all as part of a comprehensive treatment programme for the treatment of ADHD.

In agreement with the G-BA, the manufacturer cited atomoxetine as appropriate comparator therapy, but did not present any relevant studies for the comparison with lisdexamfetamine.

ADHD drugs were not used in compliance with their approval

In the only study presented (SPD489-317), lisdexamfetamine and atomoxetine were only seen as drug treatment -- without being part of a comprehensive treatment programme. This was neither sensible nor did it comply with the approval, and therefore did also not cover the appropriate comparator therapy.

There was no offer of psychological, educational or social measures, for example. There was also no consultation for the children (and parents) to adapt measures or take on other, more suitable measures, if necessary.

Moreover, it was only possible to a limited extent to continue previous ongoing non-drug treatment in the study: Only 8% of the children and adolescents continued receiving non-drug treatment. Only 22% of the study participants in total had received a non-drug treatment of ADHD before anyway.

Short-term study insufficient

ADHD is a chronic disease for which drug treatment over a longer period of time may be necessary according to the SPC of lisdexamfetamine. The study SPD489-317 had a treatment duration of 9 weeks in total and was therefore also too short to draw conclusions on an added benefit.

Hence there were several reasons why the study presented by the manufacturer was unsuitable. An added benefit of lisdexamfetamine is therefore not proven.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Added benefit of lisdexamfetamine is not proven." ScienceDaily. ScienceDaily, 3 September 2013. <www.sciencedaily.com/releases/2013/09/130903102105.htm>.
Institute for Quality and Efficiency in Health Care. (2013, September 3). Added benefit of lisdexamfetamine is not proven. ScienceDaily. Retrieved April 20, 2014 from www.sciencedaily.com/releases/2013/09/130903102105.htm
Institute for Quality and Efficiency in Health Care. "Added benefit of lisdexamfetamine is not proven." ScienceDaily. www.sciencedaily.com/releases/2013/09/130903102105.htm (accessed April 20, 2014).

Share This



More Health & Medicine News

Sunday, April 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins